Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A D Luber

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Lancet (London, England)|September 29, 2001
Standard methods to measure HIV drug concentrationsA D Luber, C Merry
Annals of Internal Medicine|March 25, 2000
Antiretroviral therapy for pregnant HIV-infected womenA D Luber, B J Dong
The Annals of Pharmacotherapy|September 1, 1996
Famciclovir for treatment of herpesvirus infectionsA D Luber, J F Flaherty
The Journal of Antimicrobial Chemotherapy|March 17, 2001
Risk factors for amphotericin B-induced nephrotoxicityA D Luber, L Maa, M Lam, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 5, 2000
Ceftriaxone therapy for staphylococcal osteomyelitis: a reviewB J Guglielmo, A D Luber, D Paletta, et al.
The Journal of Infectious Diseases|May 1, 1996
Relative importance of oral versus intravenous vancomycin exposure in the development of vancomycin-resistant enterococciA D Luber, R A Jacobs, M Jordan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 1, 1996
Hypothermia following the intravenous administration of amphotericin BT G Barlows, A D Luber, R A Jacobs, et al.
HIV Medicine|September 1, 2007
Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteersA D Luber, R Brower, D Kim, et al.
The Western Journal of Medicine|November 24, 1999
Prevention of adverse events in hospitalized patients using an antimicrobial review programB J Guglielmo, A D Luber, R L Corelli, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 19, 2001
Pharmacokinetic parameters of protease inhibitors and the Cmin/IC50 ratio: call for consensusS Becker, A Fisher, C Flexner, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Lancet (London, England)|September 29, 2001
Standard methods to measure HIV drug concentrationsA D Luber, C Merry
Annals of Internal Medicine|March 25, 2000
Antiretroviral therapy for pregnant HIV-infected womenA D Luber, B J Dong
The Annals of Pharmacotherapy|September 1, 1996
Famciclovir for treatment of herpesvirus infectionsA D Luber, J F Flaherty
The Journal of Antimicrobial Chemotherapy|March 17, 2001
Risk factors for amphotericin B-induced nephrotoxicityA D Luber, L Maa, M Lam, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 5, 2000
Ceftriaxone therapy for staphylococcal osteomyelitis: a reviewB J Guglielmo, A D Luber, D Paletta, et al.
The Journal of Infectious Diseases|May 1, 1996
Relative importance of oral versus intravenous vancomycin exposure in the development of vancomycin-resistant enterococciA D Luber, R A Jacobs, M Jordan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 1, 1996
Hypothermia following the intravenous administration of amphotericin BT G Barlows, A D Luber, R A Jacobs, et al.
HIV Medicine|September 1, 2007
Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteersA D Luber, R Brower, D Kim, et al.
The Western Journal of Medicine|November 24, 1999
Prevention of adverse events in hospitalized patients using an antimicrobial review programB J Guglielmo, A D Luber, R L Corelli, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 19, 2001
Pharmacokinetic parameters of protease inhibitors and the Cmin/IC50 ratio: call for consensusS Becker, A Fisher, C Flexner, et al.
Pageof 2